Verrica Pharmaceuticals (VRCA) delivered a split third quarter. It reported a GAAP loss of $0.58 per share, missing the -$0.50 consensus by 16.0%. Revenue of $6.91 million beat the $6.15 million estimate by 12.4%. The year-over-year comparisons look severe: earnings fell 1260.0% and revenue dropped 51.8%. Both declines stem from a $10.0 million one-time Torii milestone in the year-ago quarter, which flattered that period into a near-breakeven $0.03 loss. The more meaningful story is the commercial franchise. U.S. YCANTH net product revenue reached a record $5.7 million, up 11.9% sequentially and 57.9% year over year. That extends a steady climb from $3.7 million in Q4 2025, $4.3 million in Q1 and $5.1 million in Q2. The central tension is what is driving that growth. The record came from better monetization per prescription, not more patients.
The quality of the top-line beat deserves scrutiny. Dispensed applicator units slipped about 2.5% sequentially to 19,135 from 19,626. Sequential unit growth had been 12.1% in Q1 and 28% in Q2. Management blamed summer travel seasonality and warned that normal seasonality would also affect Q4. Revenue rose anyway because gross-to-net improved. Two factors drove that: lower co-pay assistance spending and the YCanthRx effort that routes medical-benefit claims to in-network pharmacies. Management called that lever scalable, and it is real. Still, yield gains have a ceiling that volume growth does not, and investors will want to see units resume growing. Product gross margin also eased to 89.8% from 91.5% in Q2, though it remains above Q1's 87.3%.
The earnings miss is largely an accounting story rather than a cash one. R&D jumped to $7.6 million from $2.2 million a year ago and $6.0 million in Q2. Of the year-over-year increase, $3.7 million was non-cash common-warts trial expense funded by Torii, which covers the first $40 million of program costs. On the company's non-GAAP basis, which excludes stock compensation, the loss was $0.49 per share. The non-GAAP net loss of $10.5 million was roughly flat with Q2's $10.2 million. Per-share figures also reflect dilution: weighted shares rose to 21.3 million from 9.5 million a year earlier.
The call did its best work on the pipeline. COVE-2, the first pivotal Phase 3 trial in common warts, completed enrollment after a blinded interim analysis concluded no additional patients were needed. Its topline readout is now expected in Q1 2027, ahead of the mid-2027 program timing cited last quarter. COVE-3 is more than 50% enrolled, with data expected in mid-2027. Common warts affect roughly 22 million U.S. patients and have no FDA-approved prescription therapy. Management frames the label expansion as a potential multibillion-dollar opportunity if approved. Verrica also added a VP-315 proof-of-concept plan in Gorlin syndrome, a rare disease with no approved therapy, and clinical supply is already manufactured.
The Gorlin plan comes with trade-offs, and balance-sheet bears have legitimate ammunition. Timing for the sporadic BCC Phase 3 now looks less defined. The company unlocked the remaining $15 million of its $27.5 million credit facility ahead of schedule, but the guided runway contracted to "into Q4 2027" from "into 2028" last quarter. That new figure excludes any Gorlin trial costs. Cash stood at just $14.4 million, including a $12.5 million draw. Stockholders' equity has swung to a $6.0 million deficit. The lender is an entity controlled by Chairman Paul Manning, and the loan carries a 16% IRR catch-up. Ex-U.S. supply revenue from Torii is also expected to step down as the arrangement shifts to royalties.
Investor sentiment shifted meaningfully, moving from -0.20 at the prior report to +0.24. Price action has told a harsher story. Shares closed at $3.91 before the report, down 26.4% from the $5.31 open after the August release and 28.3% below the 200-day moving average of $5.45. The stock hit a 52-week low of $3.08 on November 5 and had rebounded about 27% from there into the print. It remained a third below its late-August high of $5.86. The trend readings are mixed: momentum has turned positive while price and AVWAP trends remain negative.
The bottom line is that Verrica's quarter strengthened the catalyst path more than the commercial engine. Record YCANTH revenue and an earlier COVE-2 readout are genuine positives. But revenue growth now depends on pricing yield while unit volume stalls. Losses are widening on paper, and the runway grows tighter even as the related-party borrowing grows. Q1 2027 common-warts data has become the defining event for the stock. Until then, investors are weighing improving sentiment against a thin balance sheet.